Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
Subscribe To Our Newsletter & Stay Updated
